ARTICLE | Company News
Rottapharm S.p.A., Xytis Pharmaceuticals deal
January 17, 2005 8:00 AM UTC
Xytis received exclusive development and marketing rights to Rottapharm's neboglamine ( CR2249) to treat schizophrenia and other CNS disorders. Xytis' rights include the U.S., Canada, Japan, Australi...